18Dec 2023
US FDA approves Astellas' combination therapy for bladder cancer.

US FDA approves Astellas' combination therapy for bladder cancer.

The U.S. Food and Drug Administration has granted approval for Astellas Pharma's Padcev in conjunction with Merck's Keytruda to treat a specific type of bladder cancer. This follows the FDA's earlier accelerated approval in April for patients ineligible for cisplatin chemotherapy. The decision stems from a successful late-stage trial, meeting key efficacy criteria in overall survival and progression-free survival. Astellas, previously endorsed for its chronic eye disease drug Izervay, collaborated with Seagen (Pfizer-owned) in developing Padcev. This regulatory nod bolsters Astellas' portfolio in the pharmaceutical landscape.

  • #general medicine

Like

Save

Share